Premium
Characterization of Noni component damnacanthal in anti‐tumorigenic activity
Author(s) -
Nualsanit Thararat,
Rojanapanthu Pleumchitt,
Gritsanapan Wandee,
Baek Seung Joon
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.797.2
Subject(s) - medicine , carcinogenesis , pharmacology , cancer
Damnacanthal, an anthraquinone compound, is isolated from the roots of Morinda citrifolia L. (noni), which has been used for traditional therapy in several chronic diseases including cancer. In this report, we examined systematic approaches on the cancer suppressing capability of damnacanthal in colorectal tumorigenesis. Damnacanthal exhibits cell growth arrest as well as caspase activity induction in colorectal cancer cells. We also examined several potential target proteins and found that the pro‐apoptotic protein Nonsteroidal anti‐inflammatory activated gene‐1 (NAG‐1) is highly induced. Subsequently, we have found that damnacanthal also enhances transcription factor C/EBPβ, which controls NAG‐1 transcriptional activity. Blocking of C/EBPβ by shRNA results in the reduction of NAG‐1 expression as well as caspase activity in the presence of damnacanthal. Taken together, these results indicate that damnacanthal increases anti‐tumorigenic activity in human colorectal cancer cells, and C/EBPβ plays a role in damnacanthal‐induced NAG‐1 expression. This work was supported by NIH grant‐R01CA108975 and University of Tennessee Center of Excellence in Livestock Diseases and Human Health grant. Financial support for TN by the Royal Golden Jubilee PhD Program (PHD/0159/2546), Thailand.